Monte Rosa Therapeutics Presents Preclinical Data on MRT-6160 at ACR Convergence 2025

Monte Rosa Therapeutics, a clinical-stage biotechnology company, recently announced the presentation of preclinical data on MRT-6160, a rationally designed molecular glue degrader (MGD), at the ACR Convergence 2025 conference. The data demonstrate the potential of MRT-6160 to address multiple autoimmune and inflammatory diseases, including systemic lupus erythematosus, Sjogren's disease, and rheumatoid arthritis.

In a preclinical autoimmune disease model characterized by chronic inflammation, autoantibody production, and multi-organ involvement, administration of MRT-6160 resulted in broad activity across an array of disease markers, including attenuated autoantibody levels and reduced skin and kidney pathology. These findings reinforce the breadth of MRT-6160's potential across multiple immune-mediated diseases and highlight the potential capacity of MGDs to potently degrade otherwise 'undruggable' proteins.

Key Takeaways:

• MRT-6160, a VAV1-directed molecular glue degrader, has shown broad activity in preclinical models of multiple autoimmune and inflammatory diseases, including systemic lupus erythematosus, Sjogren's disease, and rheumatoid arthritis.
• Administration of MRT-6160 resulted in attenuated autoantibody levels and reduced skin and kidney pathology in a spontaneous autoimmune disease MRL-Fas lpr mouse model.
• MRT-6160 was equivalent or superior to prednisone or anti-CD40L monoclonal antibody treatments across multiple metrics of disease pathology.
• The data demonstrate the potential of MRT-6160 to address multiple autoimmune and inflammatory diseases with a novel, orally dosed modality blocking multiple pathogenic cytokines and secreted autoantibodies.
• Monte Rosa Therapeutics has entered into an agreement with Novartis, granting exclusive worldwide rights to develop, manufacture, and commercialize MRT-6160 and other VAV1 MGDs.
• Monte Rosa is eligible to receive up to $2.1 billion in development, regulatory, and sales milestones for MRT-6160, beginning upon initiation of Phase 2 studies.

Statistics:

• MRT-6160 demonstrated sustained, dose-dependent VAV1 degradation in peripheral blood T and B cells after single and multiple dose administration in a Phase 1 clinical trial.
• MRT-6160 inhibited secretion of inflammatory cytokines from whole blood derived T and B cells following ex vivo stimulation in a Phase 1 clinical trial.
• Up to $2.1 billion in development, regulatory, and sales milestones are available to Monte Rosa for MRT-6160, beginning upon initiation of Phase 2 studies.

Sources:

• GlobeNewswire: "Monte Rosa Therapeutics to Present Preclinical Data on MRT-6160 at ACR Convergence 2025" (October 24, 2025)
• ClinicalTrials.gov: "A Study of MRT-6160 in Healthy Volunteers" (NCT06597799)
• Monte Rosa Therapeutics website: "About MRT-6160"
• Monte Rosa Therapeutics website: "About the Company"